IAM · Insider Trading
Iambic Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by IAM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-19 | William H Rastetter | Director | C | +200,920 | — |
| 2026-10-19 | R Jacob Vogelstein | Director | C | +4,196,585 | — |
| 2026-10-19 | Evan Lockwood Rachlin | Director | MIXED | +2,646,002 | +$11.50M |
| 2026-10-19 | Michael Secora | CFO & Chief Corp Dev Ofcr | C | +61,342 | — |
| 2026-10-19 | Catalio Nexus Fund III, LP | 10%+ Owner | C | +20,982,925 | — |
| 2026-10-16 | Kurt Von Emster | Director | A | +20,300 deriv. | — |
| 2026-10-16 | Mary Tagliaferri | Director | A | +20,300 deriv. | — |
| 2026-10-16 | Frederick R Manby | Chief Technology Officer | A | +132,200 | — |
| 2026-10-16 | Shalini Sharp | Director | A | +20,300 deriv. | — |
| 2026-10-16 | R Jacob Vogelstein | Director | A | +20,300 deriv. | — |
| 2026-10-16 | Neil Josephson | Chief Medical Officer | A | +31,000 | — |
| 2026-10-16 | Peter A Olson | Chief Scientific Officer | A | +19,500 | — |
| 2026-10-16 | Thomas F. Miller | Chief Executive Officer | A | +132,200 | — |
| 2026-10-16 | Evan Lockwood Rachlin | Director | A | +20,300 deriv. | — |
| 2026-10-16 | William H Rastetter | Director | A | +40,600 deriv. | — |
| 2026-10-16 | Michael Secora | CFO & Chief Corp Dev Ofcr | A | +28,400 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Evan Lockwood Rachlin | Director | 1,869,498 | — |
| Frederick R Manby | Chief Technology Officer | 1,862,665 | — |
| R Jacob Vogelstein | Director | 1,458,290 | — |
| Thomas F. Miller | Chief Executive Officer | 1,410,756 | — |
| Catalio Nexus Fund III, LP | 10%+ Owner | 742,546 | — |
| Michael Secora | CFO & Chief Corp Dev Ofcr | 279,902 | — |
| William H Rastetter | Director | 192,579 | — |
| Neil Josephson | Chief Medical Officer | 71,459 | — |
| Peter A Olson | Chief Scientific Officer | 30,909 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IAM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.